HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.
about
Human immunodeficiency virus & cardiovascular riskInterventions for HIV-associated nephropathyInterventions for HIV-associated nephropathyA cross-sectional, facility based study of comorbid non-communicable diseases among adults living with HIV infection in ZimbabweRenal function in Ghanaian HIV-infected patients on highly active antiretroviral therapy: a case-control studyCOHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort.Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitorsRenal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapineHeart and HAART: Two sides of the coin for HIV-associated cardiology issuesA cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario.Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban settingPredictors of impaired renal function among HIV infected patients commencing highly active antiretroviral therapy in Jos, Nigeria.HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users.Urinary biomarkers of kidney diseases in HIV-infected children.Renal abnormalities among HIV infected children at Muhimbili National Hospital (MNH)-Dar es Salaam, TanzaniaHepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART RegimensPerformance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals.Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfected patients.Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy.Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.Dual inhibition of HCV and HIV by ring-expanded nucleosides containing the 5:7-fused imidazo[4,5-e][1,3]diazepine ring system. In vitro results and implications.Renal toxicity associated with antiretroviral therapy.Differentiating HIV-associated nephropathy from antiretroviral drug-induced nephropathy: a clinical challenge.Pattern and outcome of renal admissions at the University of Port Harcourt Teaching Hospital, Nigeria: A 4 years review.Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate.Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals.Membranoproliferative Glomerulonephritis Associated with a Human Immunodeficiency Virus Infection.Prevalence of renal disease within an urban HIV-infected cohort in northern Italy.The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.Nephrology consultations incorporated into HIV care - non-compliance is an important issue.Crystalluria in HIV/AIDS patients on highly active anti-retroviral therapy in the Kumasi metropolis; a cross sectional study.Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2 years.HIV associated lupus like nephropathy.Barriers to listing for HIV-infected patients being evaluated for kidney transplantation.Predictive models for maximum recommended therapeutic dose of antiretroviral drugs.The treatment of chronic hepatitis B: Focus on adefovir-like antivirals.Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
P2860
Q22241184-74C65D43-9312-49D4-9EA4-F9EE99C40291Q24201629-3C27C5DB-4129-483E-A547-7EE5DB11CD8EQ24240525-B72304E1-6AFA-4201-93A7-B91D2F1A6611Q28385694-F585B811-A2DB-4CB6-9220-A0B00B5A28AAQ28539647-40F0E5D4-67AE-49E3-9297-485643000B77Q33640397-D78400D5-A756-4C7D-B1DE-E82DC03CB384Q34136166-F675966C-913F-4CF5-88AE-B5FBFD0697DAQ34250879-51C823D2-2E80-4104-8ADE-C62885C63B2DQ34390565-849305E0-16F5-4EE0-9C58-BC86716C3A70Q35093858-F8E4B756-BE5D-43D0-8910-25F1B1B8F0D8Q35282729-52B047E5-88EC-4573-95FD-33F9A9947C48Q35542976-7B47EC85-1520-4577-B65D-F160D5555762Q35545350-1936677D-B7C3-408E-B7A5-25EC1E7503ECQ35934081-0A6A0B81-4B78-4436-BB77-51EBCD003970Q35965079-F07C48D3-0B17-4FC0-B49D-BD326A634A9EQ36334834-B2CB80C6-0D3F-4768-8B24-D164D57A8685Q36472367-DF121819-CCC1-447B-8982-339F13D9428CQ36687721-2A26EB1D-6982-4373-94F9-B5FB546C6A32Q36903905-294F0B67-0B5F-4B09-830C-CB53FFC7A0FDQ37505250-BB8536BC-7117-4C51-90B9-4C4FD1441332Q37686155-85EEFF11-5F5E-498E-82F7-98FA48EE1DF3Q37691512-E0708882-8202-44A7-8B5E-FD25A6141B1AQ38031028-5D819403-A911-4A5A-B6E5-C0AE7D337F60Q38219884-B5F31933-CCF9-4417-B391-2DB6341A8335Q38798152-9254107E-96CD-4EF6-8F0D-990BF4577A72Q39713984-77CA5B91-FE3D-4F56-8DC2-C37D89346878Q40046567-56AB9889-9F1E-4B7A-877E-6AADD27F9430Q40100513-F70FD10B-0D6B-4FB7-B001-E7B596804844Q40113698-9388BBA5-612B-492B-A5CD-A7AA1BE6E121Q40497483-00501353-4CED-4B5F-BC8D-6284005EFB84Q40541589-2D9EE6CD-C14A-4B45-A3BC-02A44871277EQ40602805-70F42FBC-559F-42A4-8439-B73DDE0CC666Q41583156-44150D38-6D82-4831-8FAD-D4259DA6C0CBQ41597280-0A51C729-2EEA-4584-AA31-87DD2F631FFCQ41756660-76503CB0-BEF8-42FA-A749-AA8CC4276287Q41935466-D71A24D1-0506-422E-BEFA-8386AC301CB2Q42589175-D5EA52DF-5999-4586-ADF9-E495E4F4D7A1Q43203226-9987AF70-C723-4E64-A109-EF9914F27C7DQ43474735-ECEDC93A-0757-428C-A422-F1AF31AF89D6Q43876123-6576C6E9-C301-4616-B66A-D2140B1B76AC
P2860
HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
HIV-associated renal diseases ...... l therapy-induced nephropathy.
@ast
HIV-associated renal diseases ...... l therapy-induced nephropathy.
@en
type
label
HIV-associated renal diseases ...... l therapy-induced nephropathy.
@ast
HIV-associated renal diseases ...... l therapy-induced nephropathy.
@en
prefLabel
HIV-associated renal diseases ...... l therapy-induced nephropathy.
@ast
HIV-associated renal diseases ...... l therapy-induced nephropathy.
@en
P2093
P2860
P356
P1476
HIV-associated renal diseases ...... l therapy-induced nephropathy.
@en
P2093
P2860
P304
P356
10.1086/503566
P407
P577
2006-04-11T00:00:00Z